A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients

Blood

Volumn 103, Issue 5, 2004, Pages 1838-1845

  Moura, Ivan C ^c   Lepelletier, Yves ^c   Arnulf, Bertrand ^c   England, Patrick ^c   Baude, Cedric ^c   Beaumont, Carole ^c   Bazarbachi, Ali ^c   Benhamou, Marc ^c   Monteiro, Renato C ^b   Hermine, Olivier ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A24; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; EQUILIBRIUM CONSTANT; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; RECEPTOR BINDING; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE;

EID: 10744221783     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2440     Document Type: Article

References (45)

1. Hinuma Y, Komoda H, Chosa T, et al. Antibodies to adult T-cell leukemia-virus-associated antigen (ATLA) in sera from patients with ATL and controls in Japan: a nation-wide sero-epidemiologic study. Int J Cancer. 1982;29:631-635.
2. Takatsuki K, Hinuma Y. Adult T-cell leukemia/lymphoma. In: Gallo RC, Wong-Staal F, eds. Retrovirus Biology and Human Disease. New York, NY: Dekker; 1990:147.
3. Bunn PA Jr, Schechter GP, Jaffe E, et al. Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N Engl J Med. 1983;309:257-264.
4. Gill PS, Harrington W Jr, Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995;332:1744-1748.
5. Hermine O, Bouscary D, Gessain A, et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med. 1995;332:1749-1751.
6. Hermine O, Allard I, Levy V, Arnulf B, Gessain A, Bazarbachi A. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J. 2002;3:276-282.
7. Bazarbachi A, Hermine O. Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13(suppl 1):S186-190.
8. Greene WC, Robb RJ. Receptors for T-cell growth factor: structure, function and expression on normal and neoplastic cells. Contemp Top Mol Immunol. 1985;10:1-34.
9. Markham PD, Salahuddin SZ, Gallo RC. In vitro cultivation of normal and neoplastic human T lymphocytes. Clin Haematol. 1984;13:423-446.
10. Waldmann TA, White JD, Goldman CK, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood. 1993;82:1701-1712.
11. Waldmann TA, White JD, Carrasquillo JA, et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood. 1995;86:4063-4075.
12. Waldmann TA. The IL-2/IL-15 receptor systems: targets for immunotherapy. J Clin Immunol. 2002;22:51-56.
13. Petrini M, Pelosi-Testa E, Sposi NM, et al. Constitutive expression and abnormal glycosylation of transferrin receptor in acute T-cell leukemia. Cancer Res. 1989;49:6989-6996.
14. Trowrbridge IS, Shackelford DA. Structure and function of transferrin receptors and their relationship to cell growth. Biochem Soc Symp. 1986;51:117-129.
15. Schneider YJ, Limet JN, Octave JN, Otte-Slachmuylder C, Crichton RR, Trouet A. The role of receptor-mediated endocytosis in iron metabolism. Prog Clin Biol Res. 1982;91:495-521.
16. Klausner RD, Ashwell G, van Renswoude J, Harford JB, Bridges KR. Binding of apotransferrin to K562 cells: explanation of the transferrin cycle. Proc Natl Acad Sci U S A. 1983;80:2263-2266
17. van Renswoude J, Bridges KR, Harford JB, Klausner RD. Receptor-mediated endocytosis of transferdn and the uptake of fe in K562 cells: identification of a nonlysosomal acidic compartment. Proc Natl Acad Sci U S A. 1982;79:6186-6190.
18. Taetle R, Honeysett JM. Gamma-interferon modulates human monocyte/macrophage transferrin receptor expression. Blood. 1988;71:1590-1595.
19. Lesley J, Hyman R, Schulte R, Trotter J. Expression of transferrin receptor on murine hematopoietic progenitors. Cell Immunol. 1984;83:14-25.
20. Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol. 1983;36:539-545.
21. Faulk WP, Hsi BL, Stevens PJ. Transferrin and transferrin receptors in carcinoma of the breast. Lancet. 1980;2:390-392.
22. Shindelman JE, Ortmeyer AE, Sussman HH. Demonstration of the transferrin receptor in human breast cancer tissue. Potential marker for identifying dividing cells. Int J Cancer. 1981;27:329-334.
23. Trowbridge IS, Lopez F. Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro. Proc Natl Acad Sci U S A. 1982;79:1175-1179.
24. Taetle R, Honeysett JM, Trowbridge I. Effects of anti-transferrin receptor antibodies on growth of normal and malignant myeloid cells. Int J Cancer. 1983;32:343-349.
25. Ng PP, Dela Cruz JS, Sorour DN, et al. An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proc Natl Acad Sci U S A. 2002;99:10706-10711.
26. Moura IC, Centelles MN, Arcos-Fajardo M, et al. Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med. 2001;194:417-425.
27. Pastorelli C, Veiga J, Charles N, et al. Phospholipid scramblase, a new effector of Fc varepsilon RI signaling in mast cells. Mol Immunol. 2002;38:1235.
28. Bazarbachi A, El-Sabban ME, Nasr R, et al. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood. 1999;93:278-283.
29. Shirono K, Hattori T, Takatsuki K. A new classification of clinical stages of adult T-cell leukemia based on prognosis of the disease. Leukemia. 1994;8:1834-1837.
30. Tordjman R, Lepelletier Y, Lemarchandel V, et al. A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nat Immunol. 2002;3:477-482.
31. Zermati Y, Garrido C, Amsellem S, et al. Caspase activation is required for terminal erythroid differentiation. J Exp Med. 2001;193:247-254.
32. Kotamraju S, Chitambar CR, Kalivendi SV, Joseph J, Kalyanaraman B. Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells: role of oxidant-induced iron signaling in apoptosis. J Biol Chem. 2002;277:17179-17187.
33. Lebron JA, Bennett MJ, Vaughn DE, et al. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell. 1998;93:111-123.
34. Vidal C, Matsushita S, Colamonici OR, Trepel JB, Mitsuya H, Neckers LM. Human T lymphotropic virus I infection deregulates surface expression of the transferrin receptor. J Immunol. 1988;141:984-988.
35. Neckers LM. Regulation of transferrin receptor expression and control of cell growth. Pathobiology. 1991;59:11-18.
36. Lesley J, Schulte R, Woods J. Modulation of transferrin receptor expression and function by anti-transferrin receptor antibodies and antibody fragments. Exp Cell Res. 1989;182:215-233.
37. Haq RU, Wereley JP, Chitambar CR. Induction of apoptosis by iron deprivation in human leukemic CCRF-CEM cells. Exp Hematol. 1995;23:428-432.
38. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79:428-437.
39. Taetle R, Castagnola J, Mendelsohn J. Mechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies. Cancer Res. 1986;46:1759-1763.
40. Mendelsohn J, Trowbridge I, Castagnola J. Inhibition of human lymphocyte proliferation by monoclonal antibody to transferrin receptor. Blood. 1983;62:821-826.
41. Hege KM, Daleke DL, Waldmann TA, Matthay KK. Comparison of anti-Tac and anti-transferrin receptor-conjugated liposomes for specific drug delivery to adult T-cell leukemia. Blood. 1989;74:2043-2052.
42. Phillips KE, Herring B, Wilson LA, et al. IL-2Ralpha-directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction. Cancer Res. 2000;60:6977-6984.
43. Zhang Z, Zhang M, Ravetch JV, Goldman C, Waldmann TA. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood. 2003;102:284-288.
44. Lehky TJ, Levin MC, Kubota R, et al. Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac. Ann Neurol. 1998;44:942-947.
45. Brooks D, Taylor C, Dos Santos B, et al. Phase la trial of murine immunoglobulin A antitransferrin receptor antibody 42/6. Clin Cancer Res. 1995;1:1259-1265.